Tvardi Therapeutics Updates Corporate Presentation on Therapies

Tvardi Therapeutics ( (TVRD) ) has issued an announcement.

On June 6, 2025, Tvardi Therapeutics updated its corporate presentation, highlighting its progress in developing therapies for fibrosis-driven diseases. The company reported encouraging trends in clinical trials for idiopathic pulmonary fibrosis and hepatocellular carcinoma, with significant data expected in late 2025 and early 2026, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (TVRD) stock is a Buy with a $65.00 price target. To see the full list of analyst forecasts on Tvardi Therapeutics stock, see the TVRD Stock Forecast page.

Spark’s Take on TVRD Stock

According to Spark, TipRanks’ AI Analyst, TVRD is a Neutral.

Cara Therapeutics’ stock is currently buoyed by strong technical momentum, with prices significantly above key moving averages and positive market indicators. However, significant financial challenges, including negative profitability and cash flow issues, weigh heavily on the stock’s long-term outlook. The lack of profitability is reflected in a negative P/E ratio, making valuation difficult and risky. Investors should be cautious of the high financial risks despite the current positive technical trends.

To see Spark’s full report on TVRD stock, click here.

More about Tvardi Therapeutics

Tvardi Therapeutics, Inc. operates in the biotechnology industry, focusing on developing therapies targeting STAT3, a central mediator in fibrosis-driven diseases. The company is advancing its product candidates for idiopathic pulmonary fibrosis and hepatocellular carcinoma, with ongoing clinical trials and a promising pipeline.

Average Trading Volume: 29,583

Technical Sentiment Signal: Hold

Current Market Cap: $266.8M

See more insights into TVRD stock on TipRanks’ Stock Analysis page.